Mumbai: Neuberg Diagnostics plans to raise about ₹3,500-4,000 crore through an initial public offering (IPO) in FY28, founder and chairman GSK Velu told ET.
The Chennai-based diagnostics company aims to raise ₹500 crore in a pre-IPO funding round over the next three to six months to finance four to five acquisitions as part of its pan-India expansion strategy, according to Velu. He said Neuberg expects to invest ₹700-1,000 crore through fresh capital, internal accruals and debt to fund its growth.
“The plan is to prepare for an IPO in FY28, potentially between April and September, depending on market conditions and readiness,” said Velu. “The IPO itself could be in the range of ₹3,500 crore to ₹4,000 crore. It is likely to include both a fresh issue and a secondary component for the existing private equity investor. Prior to the IPO, we may invest around ₹700 crore to ₹1,000 crore across acquisitions and growth initiatives.”
Neuberg specialises in new-generation diagnostic technologies. It is betting on genomics testing and longevity programmes for health and wellness as one of its key growth pillars. “We believe we can be in a strong position to emerge as the number two player. Of course, that also depends on how the broader market and competitors evolve,” he said.
Gross revenue of the company was ₹1,400 crore in FY26.
As part of its western India foray, Neuberg is launching a preventive health centre in Mumbai, which will offer new-generation tests based on genetics, pathology and radiology. New-generation tests are expected to contribute 25% of revenue within three years, up from 15% now. “Our immediate focus is on Mumbai, Maharashtra, Delhi and the NCR region,” said Velu.
“Our focus is on genomics and advanced pathology. At the same time, we have been bringing in partners with radiology capabilities because we believe the future of healthcare will be preventive, predictive and personalised,” said Kavya Velu, executive director and president of Neuberg.
